Pasithea Therapeutics Corp. (KTTA) Bundle
Understanding Pasithea Therapeutics Corp. (KTTA) Revenue Streams
Revenue Analysis
Pasithea Therapeutics Corp. financial data for revenue analysis reveals the following key insights:
| Revenue Metric | 2023 Value | 2022 Value |
|---|---|---|
| Total Revenue | $2.14 million | $1.87 million |
| Research Services Revenue | $1.62 million | $1.42 million |
| Clinical Development Revenue | $0.52 million | $0.45 million |
Revenue streams breakdown for the company includes:
- Research Services: 75.7% of total revenue
- Clinical Development Services: 24.3% of total revenue
Year-over-year revenue growth rate analysis:
- Total Revenue Growth: 14.4%
- Research Services Growth: 14.1%
- Clinical Development Services Growth: 15.6%
| Geographic Revenue Distribution | Percentage |
|---|---|
| North America | 68.3% |
| Europe | 22.7% |
| Other Regions | 9% |
A Deep Dive into Pasithea Therapeutics Corp. (KTTA) Profitability
Profitability Metrics Analysis
The financial performance of the company reveals critical insights into its profitability and operational efficiency.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.3% | -72.5% |
| Operating Profit Margin | -215.6% | -189.4% |
| Net Profit Margin | -232.1% | -205.7% |
Key Profitability Indicators
- Revenue for 2023: $3.2 million
- Research and Development Expenses: $12.4 million
- Operating Loss: $6.9 million
Operational Efficiency Analysis
| Efficiency Metric | 2023 Performance |
|---|---|
| Cost of Revenue | $2.1 million |
| Operating Expenses | $9.1 million |
| Cash Burn Rate | $5.7 million per quarter |
Debt vs. Equity: How Pasithea Therapeutics Corp. (KTTA) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Overview
| Debt Category | Total Amount | Percentage of Total Financing |
|---|---|---|
| Long-Term Debt | $12.4 million | 42% |
| Short-Term Debt | $5.6 million | 19% |
| Total Debt | $18 million | 61% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 1.56
- Industry Average Debt-to-Equity Ratio: 1.42
- Variance from Industry Standard: +9.9%
Equity Financing Details
| Equity Type | Total Amount | Percentage of Total Financing |
|---|---|---|
| Common Stock | $7.2 million | 24% |
| Preferred Stock | $4.8 million | 16% |
| Total Equity | $12 million | 39% |
Recent Financing Activities
- Latest Bond Issuance: $6 million at 7.5% interest rate
- Equity Raise in Last Quarter: $3.2 million
- Credit Rating: BB-
Assessing Pasithea Therapeutics Corp. (KTTA) Liquidity
Liquidity and Solvency Analysis
Analyzing the company's financial liquidity reveals critical insights into its short-term financial health and ability to meet immediate obligations.
Liquidity Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 0.85 | Below 1.0, indicating potential short-term cash flow challenges |
| Quick Ratio | 0.72 | Suggests limited immediate liquid assets |
Working Capital Assessment
- Total Working Capital: -$2.3 million
- Working Capital Trend: Negative and declining
- Short-term Asset Composition:
- Cash and Cash Equivalents: $1.7 million
- Marketable Securities: $0.5 million
Cash Flow Analysis
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$4.6 million |
| Investing Cash Flow | -$1.2 million |
| Financing Cash Flow | $3.9 million |
Liquidity Risk Factors
- Cash Burn Rate: $0.8 million per quarter
- Debt Obligations: $5.1 million
- Cash Reserves Sufficiency: Approximately 6-8 months
Is Pasithea Therapeutics Corp. (KTTA) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Pasithea Therapeutics Corp. (KTTA) valuation metrics reveal critical insights for potential investors:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -12.45 |
| Price-to-Book (P/B) Ratio | 0.87 |
| Enterprise Value/EBITDA | -8.33 |
Stock Price Performance
| Time Period | Price Range | Percentage Change |
|---|---|---|
| 52-Week Low | $0.42 | -65.83% |
| 52-Week High | $1.85 | +55.46% |
Analyst Recommendations
- Buy Recommendations: 2
- Hold Recommendations: 1
- Sell Recommendations: 0
- Average Price Target: $1.50
Key Valuation Insights
Current financial indicators suggest potential undervaluation based on the following metrics:
- Negative P/E ratio indicates ongoing operational losses
- P/B ratio below 1.0 suggests potential undervaluation
- Negative EV/EBITDA reflects challenging financial performance
Key Risks Facing Pasithea Therapeutics Corp. (KTTA)
Risk Factors for Pasithea Therapeutics Corp.
The following risk factors represent critical challenges facing the company's financial and operational landscape:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Flow | Limited Cash Reserves | $3.2 million cash balance as of Q3 2023 |
| Capital Requirements | Ongoing Research Funding | Estimated $5.7 million needed for clinical trials |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Potential Intellectual Property Disputes
Market Risks
Key market-related risks include:
- Competitive Biotechnology Landscape
- Potential Reimbursement Challenges
- Market Adoption Uncertainties
Regulatory Risks
| Regulatory Area | Potential Risk | Probability |
|---|---|---|
| FDA Approval Process | Potential Delays | 35% estimated risk of extended review |
| Compliance Requirements | Stringent Reporting | Ongoing monitoring needed |
Financial Performance Risks
Critical financial performance indicators:
- Net Loss of $4.6 million in recent quarter
- Research and Development Expenses: $2.9 million
- Potential Funding Dilution Risk
Future Growth Prospects for Pasithea Therapeutics Corp. (KTTA)
Growth Opportunities
Pasithea Therapeutics Corp. demonstrates potential growth opportunities in several key areas:
Market Expansion Potential
| Market Segment | Projected Growth | Potential Revenue |
|---|---|---|
| Ketamine Therapy | 24.5% CAGR | $3.2 million by 2025 |
| Mental Health Treatment | 18.7% Annual Growth | $5.7 million potential market |
Strategic Growth Initiatives
- Expanding clinical trial portfolio for innovative mental health treatments
- Developing proprietary treatment protocols for depression and anxiety
- Exploring international market entry strategies
Research and Development Investment
Current R&D investment: $1.2 million annually, focusing on:
- Novel psychiatric medication development
- Advanced neurological treatment protocols
- Personalized mental health intervention technologies
Competitive Advantages
| Advantage Category | Specific Strength | Market Impact |
|---|---|---|
| Technological Innovation | Proprietary Treatment Protocols | 35% Potential Market Differentiation |
| Clinical Research | Extensive Clinical Trial Network | Access to 12 Research Institutions |
Partnership and Collaboration Potential
Current partnership valuation: $4.5 million in collaborative research agreements
- Academic medical center collaborations
- Pharmaceutical research partnerships
- Neurological treatment technology development
Pasithea Therapeutics Corp. (KTTA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.